Skip to main content

COVID-19 Topic Center

Breast Cancer News

Conference Insider
Compared with those with private insurance, participants in breast cancer clinical trials with Medicare, Medicaid, or other government insurance were less likely to complete trials and had a lower survival rate. Researchers presented their findings during a session at the San Antonio Breast Cancer…
Conference Insider
Most clinical trials supporting US Food and Drug Administration (FDA) approval of drugs for metastatic breast cancer over the past 13 years did not meet thresholds for substantial clinical benefit on two of three established measures, according to research presented at the San Antonio Breast Cancer…
Conference Insider
The most cost-effective treatment strategy for women with HER2-positive stage II to III breast cancer in a simulated clinical practice cohort was neoadjuvant trastuzumab + paclitaxel + pertuzumab followed by adjuvant trastuzumab for patients with pathologic complete response and by adjuvant dose-…
News
The use of intensity modulated radiation therapy (IMRT) after lumpectomy in early-stage breast cancer is associated with an average $8499 more in Medicare expenditures yet yields no expected major clinical benefit compared with conventional radiotherapy, according to a study published online in…
News
Breast reconstruction performed at hospitals in uncompetitive markets tends to cost less yet yields similar clinical outcomes as reconstruction at hospitals in more competitive markets, according to a study published recently in Annals of Surgery. “This suggests that some of the economies of…
News
Offering financial incentives to primary care providers to boost the rate of cancer screenings may result in small gains for colorectal cancer screening, but the effects are weaker for breast and cervical cancer screenings. Researchers published their findings online in the journal Health Policy…
News
Unselected genetic testing of all women following breast cancer diagnosis appears highly cost-effective compared with the standard practice of testing select women based on clinical criteria or family history, according to a study published online in JAMA Oncology.  “Our analysis suggests that an…
News
Progression of metastatic breast cancer, metastatic colorectal cancer, and metastatic lung cancer is associated with higher 12-month health care costs, according to a study that looked at real-world incremental costs of disease progression recently published in The Oncologist.  “To reduce health…
News
In a Managed Care Learning Network session, Adam M Brufsky, MD, PhD, and Edward Li, PharmD, MPH, outlined the clinical and cost implication of HER2+ breast cancer treatment in the era of biosimilars, clinical pathways, and precision medicine. Dr Brufsky, professor of medicine and associate chief…
News
HER2+ breast cancer is a clinically distinct entity, due to the striking efficacy of targeted HER2 drugs, both in early stage and metastatic breast cancer (MBC). In the early 1980s, HER2 gene amplification resulting in excess HER2 protein in breast cancer cells, was discovered to stimulate excess…
Back to Top